PL3083681T3 - Terapia amyloidozy transtyretynowej oparta na przeciwciałach (ttr) i przeznaczone dla niej pochodzące od człowieka przeciwciała - Google Patents
Terapia amyloidozy transtyretynowej oparta na przeciwciałach (ttr) i przeznaczone dla niej pochodzące od człowieka przeciwciałaInfo
- Publication number
- PL3083681T3 PL3083681T3 PL14833579T PL14833579T PL3083681T3 PL 3083681 T3 PL3083681 T3 PL 3083681T3 PL 14833579 T PL14833579 T PL 14833579T PL 14833579 T PL14833579 T PL 14833579T PL 3083681 T3 PL3083681 T3 PL 3083681T3
- Authority
- PL
- Poland
- Prior art keywords
- transthyretin
- ttr
- amyloidosis
- antibody
- human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7047—Fibrils-Filaments-Plaque formation
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13199251 | 2013-12-20 | ||
| EP14833579.7A EP3083681B1 (en) | 2013-12-20 | 2014-12-22 | Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor |
| PCT/EP2014/079094 WO2015092077A1 (en) | 2013-12-20 | 2014-12-22 | Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3083681T3 true PL3083681T3 (pl) | 2020-12-28 |
Family
ID=49876487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14833579T PL3083681T3 (pl) | 2013-12-20 | 2014-12-22 | Terapia amyloidozy transtyretynowej oparta na przeciwciałach (ttr) i przeznaczone dla niej pochodzące od człowieka przeciwciała |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10344080B2 (pl) |
| EP (1) | EP3083681B1 (pl) |
| JP (4) | JP6623159B2 (pl) |
| KR (2) | KR102496162B1 (pl) |
| CN (2) | CN111471106A (pl) |
| AU (1) | AU2014369793B2 (pl) |
| BR (1) | BR112016014328B1 (pl) |
| CA (2) | CA3177155A1 (pl) |
| CY (1) | CY1123329T1 (pl) |
| DK (1) | DK3083681T3 (pl) |
| EA (1) | EA201691060A1 (pl) |
| ES (1) | ES2815527T3 (pl) |
| HR (1) | HRP20201296T1 (pl) |
| HU (1) | HUE051837T2 (pl) |
| IL (1) | IL246048B (pl) |
| LT (1) | LT3083681T (pl) |
| MX (1) | MX2016008250A (pl) |
| NZ (2) | NZ760022A (pl) |
| PE (2) | PE20210650A1 (pl) |
| PL (1) | PL3083681T3 (pl) |
| PT (1) | PT3083681T (pl) |
| RS (1) | RS60774B1 (pl) |
| SG (1) | SG11201604831QA (pl) |
| SI (1) | SI3083681T1 (pl) |
| WO (1) | WO2015092077A1 (pl) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
| PT3083681T (pt) * | 2013-12-20 | 2020-09-03 | Neurimmune Holding Ag | Terapia à base de anticorpos de amiloidose de transtiretina (ttr) e anticorpos de origem humana para esse fim |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| IL272773B1 (en) | 2017-08-22 | 2024-02-01 | Biogen Ma Inc | Pharmaceutical preparations containing anti-amyloid cell antibodies |
| AU2018338790B2 (en) * | 2017-09-29 | 2022-09-15 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized TTR locus and methods of use |
| JP7292569B2 (ja) * | 2017-10-06 | 2023-06-19 | ノボ ノルディスク エー／エス | トランスサイレチンを検出する方法 |
| JP7357609B2 (ja) | 2017-10-06 | 2023-10-06 | ノボ ノルディスク エー／エス | 抗トランスサイレチン抗体 |
| SG11202004187UA (en) | 2017-11-29 | 2020-06-29 | Prothena Biosciences Ltd | Lyophilized formulation of a monoclonal antibody against transthyretin |
| EP3814376A4 (en) * | 2018-06-26 | 2022-07-06 | Mor Research Applications Ltd. | ANTI-TRANSTHYRETIN ANTIBODIES AND THEIR USES |
| US20210400932A1 (en) | 2018-11-09 | 2021-12-30 | Neurimmune Ag | Patient-derived amyloid xenograft non-human animal model |
| JP2022534867A (ja) | 2019-06-04 | 2022-08-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ベータスリップ変異を有するヒト化ｔｔｒ遺伝子座を含む非ヒト動物と使用方法 |
| CA3140208A1 (en) * | 2019-07-08 | 2021-01-14 | Amgen Inc. | Multispecific transthyretin immunoglobulin fusions |
| CA3158491A1 (en) | 2019-10-24 | 2021-04-29 | Novago Therapeutics Ag | Novel anti-nogo-a antibodies |
| WO2021168156A1 (en) * | 2020-02-20 | 2021-08-26 | Prothena Biosciences Limited | Monitoring transthyretin amyloidosis |
| CA3172824A1 (en) | 2020-05-12 | 2021-11-18 | Neurimmune Ag | Combination therapy for ttr amyloidosis |
| JP2023535024A (ja) * | 2020-07-23 | 2023-08-15 | オター プロシーナ リミテッド | 抗ａベータ抗体 |
| WO2022066899A1 (en) * | 2020-09-23 | 2022-03-31 | The Johns Hopkins University | Method to improve protein quality control |
| WO2023086989A1 (en) * | 2021-11-12 | 2023-05-19 | Adrx, Inc. | Transthyretin (ttr) monomer binding antibodies |
| CN114058636A (zh) * | 2021-11-16 | 2022-02-18 | 大连润生康泰医学检验实验室有限公司 | 一种转甲状腺素蛋白基因的克隆、表达与纯化方法 |
| WO2023099788A1 (en) | 2021-12-03 | 2023-06-08 | Neurimmune Ag | Novel potency assay for antibody-based drugs and useful means therefor |
| EP4296279A1 (en) * | 2022-06-23 | 2023-12-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anti-transthyretin (ttr) binding proteins and uses thereof |
| CN115125316A (zh) * | 2022-08-19 | 2022-09-30 | 中国医学科学院北京协和医院 | 肠道菌群在诊断转甲状腺素蛋白淀粉样变性中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008034016A2 (en) * | 2006-09-15 | 2008-03-20 | Foldrx Pharmaceuticals, Inc. | Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins |
| SI2436696T1 (sl) * | 2007-01-05 | 2017-10-30 | University Of Zurich | Anti-beta-amiloidno protitelo in načini njegove uporabe |
| IL184478A (en) | 2007-07-08 | 2017-07-31 | Hadasit Medical Res Services & Development Ltd | Preparations, methods and kits for identifying carriers of mutations in genes 1brca and 2brca and for the early detection of cancers associated with mutations in these genes |
| SG178809A1 (en) * | 2007-10-05 | 2012-03-29 | Genentech Inc | Use of anti-amyloid beta antibody in ocular diseases |
| JP2011506614A (ja) * | 2007-12-17 | 2011-03-03 | ダイアックス コーポレーション | Ｍｍｐ−１４結合タンパク質を含む、骨溶解性障害を処置するための組成物および方法 |
| CA2710984C (en) * | 2007-12-28 | 2018-05-29 | Elan Pharmaceuticals, Inc. | Treatment and prophylaxis of amyloidosis |
| WO2010030203A1 (en) * | 2008-09-09 | 2010-03-18 | Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. | Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr |
| EP2342220B1 (en) | 2008-10-06 | 2021-05-12 | The University Of British Columbia | Methods and systems for predicting misfolded protein epitopes |
| JP2010195710A (ja) * | 2009-02-25 | 2010-09-09 | Kumamoto Univ | アミロイド線維形成抑制剤及びその利用 |
| JP2016514091A (ja) | 2013-02-08 | 2016-05-19 | ミスフォールディング ダイアグノスティクス， インコーポレイテッド | トランスサイレチン抗体およびその使用 |
| PT3083681T (pt) * | 2013-12-20 | 2020-09-03 | Neurimmune Holding Ag | Terapia à base de anticorpos de amiloidose de transtiretina (ttr) e anticorpos de origem humana para esse fim |
| JP6818268B2 (ja) | 2014-01-29 | 2021-01-20 | Ｋｍバイオロジクス株式会社 | 抗トランスサイレチンヒト化抗体 |
-
2014
- 2014-12-22 PT PT148335797T patent/PT3083681T/pt unknown
- 2014-12-22 EP EP14833579.7A patent/EP3083681B1/en active Active
- 2014-12-22 JP JP2016541159A patent/JP6623159B2/ja active Active
- 2014-12-22 PE PE2020002162A patent/PE20210650A1/es unknown
- 2014-12-22 CA CA3177155A patent/CA3177155A1/en active Pending
- 2014-12-22 LT LTEP14833579.7T patent/LT3083681T/lt unknown
- 2014-12-22 EA EA201691060A patent/EA201691060A1/ru unknown
- 2014-12-22 SG SG11201604831QA patent/SG11201604831QA/en unknown
- 2014-12-22 CN CN202010121489.3A patent/CN111471106A/zh active Pending
- 2014-12-22 SI SI201431636T patent/SI3083681T1/sl unknown
- 2014-12-22 PL PL14833579T patent/PL3083681T3/pl unknown
- 2014-12-22 HU HUE14833579A patent/HUE051837T2/hu unknown
- 2014-12-22 CN CN201480076058.2A patent/CN106255702B/zh active Active
- 2014-12-22 AU AU2014369793A patent/AU2014369793B2/en active Active
- 2014-12-22 KR KR1020167018915A patent/KR102496162B1/ko active IP Right Grant
- 2014-12-22 RS RS20201093A patent/RS60774B1/sr unknown
- 2014-12-22 WO PCT/EP2014/079094 patent/WO2015092077A1/en active Application Filing
- 2014-12-22 NZ NZ760022A patent/NZ760022A/en unknown
- 2014-12-22 CA CA2933008A patent/CA2933008A1/en active Pending
- 2014-12-22 KR KR1020227029796A patent/KR20220123754A/ko not_active Application Discontinuation
- 2014-12-22 PE PE2016000834A patent/PE20161093A1/es unknown
- 2014-12-22 DK DK14833579.7T patent/DK3083681T3/da active
- 2014-12-22 NZ NZ721048A patent/NZ721048A/en unknown
- 2014-12-22 ES ES14833579T patent/ES2815527T3/es active Active
- 2014-12-22 US US15/106,176 patent/US10344080B2/en active Active
- 2014-12-22 BR BR112016014328-0A patent/BR112016014328B1/pt active IP Right Grant
- 2014-12-22 MX MX2016008250A patent/MX2016008250A/es unknown
-
2016
- 2016-06-06 IL IL246048A patent/IL246048B/en unknown
-
2019
- 2019-05-15 US US16/413,335 patent/US11180545B2/en active Active
- 2019-09-13 JP JP2019166797A patent/JP6841449B2/ja active Active
-
2020
- 2020-08-19 HR HRP20201296TT patent/HRP20201296T1/hr unknown
- 2020-09-10 CY CY20201100858T patent/CY1123329T1/el unknown
-
2021
- 2021-02-03 JP JP2021015375A patent/JP7258366B6/ja active Active
- 2021-11-22 US US17/532,292 patent/US20220144928A1/en active Pending
-
2023
- 2023-02-01 JP JP2023013697A patent/JP2023061993A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL246048B (en) | Treatment for transthyretin amyloidosis is antibody-based and human-derived antibodies for it | |
| EP2953970A4 (en) | TRANSTYRETIN ANTIBODIES AND USES THEREOF | |
| HK1223953A1 (zh) | 人源化的抗- 抗體和使用方法 | |
| IL245617B (en) | Humanized antibody against kallikrein-2 | |
| GB2521191B (en) | Magnetic materials and methods for their manufacture | |
| IL240443A0 (en) | Antibodies against tnf-a with a high level of galactosylation and their uses | |
| GB201319161D0 (en) | Multivalent antigen-binding protein molecules | |
| EP2965047A4 (en) | FRAME FOR MAGNETIC FLOWMETER ASSEMBLY | |
| GB201317467D0 (en) | Magnetic glasses | |
| EP2951384A4 (en) | MAGNETIC VALVE ASSEMBLY | |
| EP3022532A4 (en) | Magnetic flowmeter | |
| ZA201508081B (en) | Monoclonal antibody directed against cxcr5 | |
| GB201302878D0 (en) | Modified igG molecules | |
| HK1223950A1 (zh) | 單克隆 抗體及其用途 | |
| EP2951845A4 (en) | SPRING MAGNETIC DEVICE | |
| GB201311956D0 (en) | Magnetic Assembly | |
| EP2963657A4 (en) | FLEXIBLE MAGNETIC FILM | |
| GB201416402D0 (en) | Miniature ion source of fixed geometry | |
| EP2955728A4 (en) | MAGNETIC SUBSTANCE | |
| FI10280U1 (fi) | Magneettilukko | |
| GB201316782D0 (en) | Miniature ion source of fixed geometry |